HRR Biological Pathways Reviews

Videos

Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD

Videos

Selecting PARP Inhibitors for Patients With ER-Positive Early Breast Cancer

12/12/2023

Featuring Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD

Featuring Cynthia Ma, MD; Neelima Vid...

Cynthia Ma, MD, leads part 3 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting PARP inhibitors for patients with ER-positive early breast cancer.

Cynthia Ma, MD, leads part 3 of...

12/12/2023

Oncology

Shahneen Sandhu, MBBS, Peter MacCallum Cancer Centre

Videos

Prevalence of DNA Repair Defects Among Patients With Metastatic Prostate Cancer

11/02/2023

Featuring Shahneen Sandhu, MBBS

Featuring Shahneen Sandhu, MBBS ...

In a prospective observational study, approximately 14% of patients with metastatic prostate cancer harbored at least 1 HRR gene alteration, most commonly BRCA.

In a prospective observational...

11/02/2023

Oncology

Elena Castro, MD, PhD Hospital Universitario 12 de Octubre

Videos

Niraparib Plus Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Alterations

11/01/2023

Featuring Elena Castro, MD, PhD

Featuring Elena Castro, MD, PhD ...

Elena Castro, MD, shares final results from the MAGNITUDE study evaluating niraparib plus abiraterone acetate plus prednisone for patients with metastatic castration-resistant prostate cancer and HRR gene alterations.

Elena Castro, MD, shares final...

11/01/2023

Oncology

Eleni Efstathiou, MD, Houston Methodist Cancer Center

Videos

Niraparib Plus Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer and HRR Alterations

02/27/2023

At 2023 ASCO Genitourinary Cancers Symposium, Eleni Efstathiou, MD, shared phase 3 data which support the use of niraparib with abiraterone acetate and prednisone among patients with metastatic castration-resistant prostate cancer and BRCA...

At 2023 ASCO Genitourinary...

02/27/2023

Oncology

Videos

Innovation and the Future Development of Cell Therapies for Patients With B-Cell Lymphomas

08/05/2024

At the 2024 Pan Pacific Lymphoma Conference, Nirav Shah, MD, discusses innovation and the future development of cell therapies for patients with various types of B-cell malignancies.

At the 2024 Pan Pacific Lymphoma...

08/05/2024

Oncology

Videos

Exploring Triplet Therapy for Patients With AML Ineligible for Intensive Induction Chemotherapy

08/05/2024

Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.

Curtis Lachowiez, MD,...

08/05/2024

Oncology

Videos

Best Management Practices for a Patient With Early-Stage Non-Small Cell Lung Cancer

08/02/2024

Ticiana Leal, MD, discusses the course of treatment she would take for a patient with early-stage NSCLC.

Ticiana Leal, MD, discusses the...

08/02/2024

Oncology

Conference Coverage

Chemotherapy and Liver Transplantation for Patients With Unresectable Colorectal Liver Metastases

08/02/2024

Rene Adam, MD, PhD, discusses results from the TRANSMET trial which demonstrated that liver transplantation combined with chemotherapy significantly improved survival among patients with unresectable colorectal liver metastases.

Rene Adam, MD, PhD, discusses...

08/02/2024

Oncology

Videos

Should Additional BCMA Therapy be Utilized After Prior BCMA Treatment for Multiple Myeloma?

07/31/2024

Ajai Chari, MD, participated in a debate at the 2024 Great Debates & Updates meeting in which he argued in favor of using additional BCMA-directed therapy after prior BCMA-directed therapy for patients with multiple myeloma.

Ajai Chari, MD, participated in...

07/31/2024

Oncology

Videos

Should Stem Cell Transplantation be Suggested for Older Patients With Multiple Myeloma?

07/31/2024

Ajai Chari, MD, participated in a debate at the 2024 Great Debates & Updates meeting in which he argued against the use of stem cell transplantation for patients with multiple myeloma over the age of 65.

Ajai Chari, MD, participated in...

07/31/2024

Oncology

Videos

Evaluating the Efficacy of R-Mini-CHOP With or Without Oral Azacytidine for Elderly Patients With DLBCL

07/29/2024

Elizabeth Brem, MD, shares expert insight into a clinical trial examining elderly patients with DLBCL treated with rituximab and reduced dose cyclophosphamide, hydroxydaunorubicin, vincristine sulfate, and prednisone with or without oral...

Elizabeth Brem, MD, shares...

07/29/2024

Oncology

Videos

CAR T-Cell Therapy vs Other Novel Therapies for Elderly Patients With Relapsed DLBCL

07/29/2024

At the 2024 Great Debates & Updates meeting, Elizabeth Brem, MD, shares expert insight on the role of CAR T-cell therapies versus other novel therapies for treating older patients with relapsed diffuse large B-cell lymphoma.

At the 2024 Great Debates &...

07/29/2024

Oncology

Videos

Benefits of Utilizing CAR-T in Later Lines of Therapy for Patients With Multiple Myeloma

07/28/2024

At the 2024 Great Debates & Updates meeting, Rahul Banerjee, MD, participated in a debate in which he argued against the use of CAR T-cell therapy in earlier lines of therapy among patients with multiple myeloma.

At the 2024 Great Debates &...

07/28/2024

Oncology

Videos

Should Autologous Stem Cell Transplantation be Considered for Older Patients With Multiple Myeloma?

07/28/2024

At the 2024 Great Debates & Updates meeting, Amrita Krishnan, MD, argued for the value of considering autologous stem cell transplantation for certain patients over the age of 65, emphasizing the benefit of assessing frailty as a complex and...

At the 2024 Great Debates &...

07/28/2024

Oncology

News

Conference Coverage

Olaparib Plus Abiraterone and Prednisone Improved Progression-Free Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations

01/25/2024

Allison Casey

According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...

According to a phase 2 trial,...

01/25/2024

Oncology

News

Novel Genomic Instability Scar Test for Detecting Homologous Repair Deficiency, Predicting Olaparib Sensitivity Among Patients With Ovarian Cancer

10/16/2023

Allison Casey

The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.

The novel, academic-developed...

10/16/2023

Oncology

News

PARP Inhibitor Plus Androgen Receptor Signaling Inhibitor Combinations for Metastatic Castration-Resistant Prostate Cancer

09/26/2023

Allison Casey

A quantitative synthesis and meta-analysis confirmed the efficacy and safety of PARP inhibitor plus androgen receptor signaling inhibitor combinations for the treatment of patients with metastatic castration-resistant prostate cancer.

A quantitative synthesis and...

09/26/2023

Oncology

News

Niraparib Plus Abiraterone Acetate and Prednisone Continues to Benefit Patients with HRR-Altered Metastatic Castration-Resistant Prostate Cancer

09/14/2023

Allison Casey

In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...

In the second interim analysis...

09/14/2023

Oncology

News

Maintenance Niraparib Extended PFS Among Patients With Advanced Ovarian Cancer

07/26/2023

Stephanie Holland

According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.

According to results from the...

07/26/2023

Oncology

News

Talazoparib With Enzalutamide Approved for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

06/21/2023

On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.

On June 20, 2023, the US FDA...

06/21/2023

Oncology

News

FDA Approves Olaparib for HRR Gene-Mutated mCRPC

05/20/2020

The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.

The FDA has approved olaparib...

05/20/2020

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology

Quizzes

Quiz

Maintenance Selinexor for Patients With Advanced or First-Line Recurrent TP53 Wild-Type Endometrial Cancer

08/08/2024

Do you know whether maintenance selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer?

Do you know whether maintenance...

08/08/2024

Oncology

Quiz

08/08/2024

Based on results from the phase 3 RUBY trial, the FDA expanded the approval of dostarlimab plus chemotherapy to include all patients with primary advanced or recurrent endometrial cancer. Do you know what the recommended dose of dostarlimab...

Based on results from the phase...

08/08/2024

Oncology

Quiz

Everolimus Plus Endocrine Therapy for Patients With Early Breast Cancer

08/05/2024

True or False: According to results from the phase 3 SWOG S127 study, the addition of everolimus, an mTOR inhibitor, to endocrine therapy did not improve survival outcomes among patients with high-risk, hormone receptor (HR)-positive,...

True or False: According to...

08/05/2024

Oncology

Quiz

Improving Long-Term Outcomes for Patients With HER2-Positive Early-Stage Invasive Breast Cancer

07/15/2024

According to the final analysis of the phase 2 ATEMPT trial, which of the following therapies demonstrated more favorable long-term outcomes among patients with HER2-positive early-stage invasive breast cancer?

According to the final analysis...

07/15/2024

Oncology

Quiz

Ibrutinib Plus Venetoclax For Patients With TP53-Mutated Mantle Cell Lymphoma

07/12/2024

Oncology

Quiz

Weekly Combination Therapy for Patients With R/R Multiple Myeloma

07/11/2024

Oncology

Quiz

Examining the Efficacy of Azacitidine Plus Ruxolitinib in Myelofibrosis Treatment

07/03/2024

Oncology

Quiz

FDA Approval of Lisocabtagene Maraleucel for MCL

07/01/2024

Oncology

Quiz

Carboplatin Plus Standard Chemotherapy for Patients With Early-Stage Triple-Negative Breast Cancer

06/28/2024

True or False: As reported in the phase 3 PEARLY trial, the addition of carboplatin to standard anthracycline and taxane therapy significantly improved event-free survival among patients with early-stage triple-negative breast cancer (TNBC).

True or False: As reported in...

06/28/2024

Oncology

Quiz

Treatment Options for a Patient With Early-Stage Non-Small Cell Lung Cancer

06/26/2024

What adjuvant treatment would you recommend?

What adjuvant treatment would...

06/26/2024

Oncology

HRR

ALIASES

Human recombination repair

References

Homologous recombination repair (HHR) is a DNA repair mechanism that removes damaged DNA by acting on double-strand breaks, interstrand crosslinks, and other kinds of DNA damage.¹ DNA damage is repaired with high fidelity by correcting damage with information copied from a homologous undamaged molecule.² Defects in HRR are present in some cancers.³

Recent News

Conference Coverage

Olaparib Plus Abiraterone and Prednisone Improved Progression-Free Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations

01/25/2024

Allison Casey

According to a phase 2 trial,...

01/25/2024

Oncology

News

Novel Genomic Instability Scar Test for Detecting Homologous Repair Deficiency, Predicting Olaparib Sensitivity Among Patients With Ovarian Cancer

10/16/2023

Allison Casey

The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.

The novel, academic-developed...

10/16/2023

Oncology

News

PARP Inhibitor Plus Androgen Receptor Signaling Inhibitor Combinations for Metastatic Castration-Resistant Prostate Cancer

09/26/2023

Allison Casey

A quantitative synthesis and...

09/26/2023

Oncology

News

Niraparib Plus Abiraterone Acetate and Prednisone Continues to Benefit Patients with HRR-Altered Metastatic Castration-Resistant Prostate Cancer

09/14/2023

Allison Casey

In the second interim analysis...

09/14/2023

Oncology

News

Maintenance Niraparib Extended PFS Among Patients With Advanced Ovarian Cancer

07/26/2023

Stephanie Holland

According to results from the...

07/26/2023

Oncology

News

Talazoparib With Enzalutamide Approved for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

06/21/2023

On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.

On June 20, 2023, the US FDA...

06/21/2023

Oncology

News

FDA Approves Olaparib for HRR Gene-Mutated mCRPC

05/20/2020

The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.

The FDA has approved olaparib...

05/20/2020

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas